New drug cocktail aims to fight advanced uterine cancer
NCT ID NCT05077215
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This Phase 3 trial tests whether adding the drug EG-007 to a standard combination of lenvatinib and pembrolizumab helps people with advanced or recurrent endometrial cancer live longer without their cancer growing. About 450 participants will be randomly assigned to receive either the three-drug combo or the standard two-drug combo. The study is not yet recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
EG-007 (a repurposed drug) plus lenvatinib and pembrolizumab
What this could lead to
If successful, this could provide a new treatment option that slows cancer growth and improves survival for people with advanced endometrial cancer.
What could go wrong
This is an early-stage Phase 3 trial that hasn't started recruiting yet. Adding EG-007 may not improve outcomes and could increase side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED ENDOMETRIAL CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••